Mayfield is a global venture capital firm with a people-first philosophy and a 50+ year track record of inception and investing, partnering with founders to build iconic enterprise, consumer, and engineering biology companies. Since its founding, the firm has invested in more than 500 companies, resulting in 119 IPOs and more than 200 acquisitions, and currently has $2.5B under management.

Mayfield Fund

Keiretsu Forum is an investment community of accredited private equity investors, venture capitalists and corporate/institutional investors. Forum members invest in high-quality, diverse investment opportunities. The community is strengthened through its involvement in social and charitable activities.  They are a worldwide network of capital, resources and deal flow with chapters in Andalucía, Barcelona, Beijing, Boise, Chennai, India, Donostia/San Sebastián, East Bay, Istanbul, Kirkland-Eastside, London, Los Angeles, Madrid, Miami, New York, North Bay, Orange County, Paris, Philadelphia, Pittsburgh, Portland, San Diego, San Francisco, Seattle, Shanghai, Silicon Valley, Singapore, Spokane-Inland, Tel Aviv, Toronto, Vancouver, Ventura County, Victoria-Vancouver Island/BC , Washington D.C., Waterloo-Wellington  ''Keiretsu'' definition Keiretsu is a Japanese term describing a group of affiliated corporations with broad power and reach. Keiretsu Forum is described as a conglomeration of individuals or small companies that are organized around private equity funding for mutual benefit. Keiretsu Forum believes that through a holistic approach that includes interlocking relationships with partners and key resources, they can offer an association that produces the highest quality deal-flow and investment opportunities.

Keiretsu Forum

Tech Coast Angels is the largest angel investor group in the United States, possessing more than 300 members in five networks in Los Angeles, Orange County, San Diego, Central Coast, and the Inland Empire. Its members provide funding and guidance to more early-stage, high-growth companies in Southern California than any other investment group.  Members invest in companies in a wide range of industries, including the life sciences, biotech, IT, services, retail, Internet, financial, software, media, consumer products, and tech startups. TCA as a whole gives companies more than just capital; they also provide counsel, mentoring, and access to an extensive network of potential investors, customers, strategic partners, and management talent.   Tech Coast Angels has been ranked by CB Insights to be among the Top 20 Angel Groups in the US; TCA was also ranked as #1 for Network Centrality, meaning we have more connections than anyone! If you are in the game-changing business, we are here to help.

Tech Coast Angels

Sand Hill Angels is a group of Silicon Valley angel investors passionate about helping entrepreneurs get to the next level. What makes the group unique is the collective experience of its members building and scaling deep technology companies. The group has been around for more than two decades. Sand Hill Angels works openly and collaboratively with venture capital funds, other angel organizations, and the Bay Area ecosystem that fosters the growth of technology startups.  For additional information, visit www.sandhillangels.com or follow @SandHillAngels.com on Twitter.

Sand Hill Angels

Life Science Angels, Inc. (LSA) is the premier angel investment group focused solely on healthcare investing, including medical devices, diagnostics, pharmaceuticals, biotechnology, and digital health.

Life Science Angels

Cota Capital is an SEC-registered multi-stage investment firm focused on private and public enterprise technology companies. Cota has invested in more than 100 private and public technology companies since inception. Cota’s overall Mission is to deliver impactful outcomes through principle-guided investment in modern enterprise technologies.

Cota Capital

StartX is a 501(c)(3) Stanford-affiliated nonprofit in Silicon Valley that runs one of the world’s top startup accelerator programs. Its mission is to advance the development of the best entrepreneurs through experiential education and peer learning. Since launching in 2010, it has supported more than 450 companies and 1000 entrepreneurs, from early to pre-IPO stage, working across a wide spectrum of industries.    StartX and StartX Med, dedicated to medical and biotechnology innovation, provide founders with access to a powerful network of entrepreneurs, investors, mentors, and industry partners, along with office space and a variety of other resources. Based in Palo Alto, the accelerator also operates StartX-QB3 Labs and the Stanford-StartX Fund. We are funded by Stanford University, Stanford Health Care, Microsoft, Steelcase, Hyundai, Oriza Ventures, Nissan, Panasonic, Lightspeed Venture Partners, Analog Devices, Silicon Valley Bank, Greylock Partners, Sequoia Capital, and many others. For more information, visit startx.com The company is associated investment vehicle, the Stanford-StartX Fund is a partnership between StartX, Stanford University and Stanford Health Care.  It can invest only in StartX companies who raise qualified rounds of venture capital using objective criteria; it is founder opt-in.

StartX (Stanford-StartX Fund)

Agilent provides laboratory solutions to meet the needs of analytical scientists and clinical researchers worldwide. Agilent works closely with customers to help address global trends that impact human health and the environment and to anticipate future scientific needs. Agilent's solutions improve the efficiency of the entire laboratory, from sample prep to data interpretation and management.

Agilent Technologies

Labcorp specializes in providing physicians with laboratory tests.  They develop new tests that provide enhanced accuracy and additional clinical information.  Their customers include physicians and their patients, hospitals and managed care plans, private employers, military and law enforcement agencies, and pharmaceutical and biotechnology companies.

LabCorp

Keiretsu Capital provides access to proprietary deal flow to its investors. Keiretsu Capital works to increase the value of investments undertaken by Keiretsu Forum members by assisting in the successful presentation of the portfolio companies to investors including syndicate partners, venture capitalists, corporate investors, and the public markets. It aims to provide significant capital appreciation through investment in high quality emerging companies that have been funded by the world’s largest angel investor network, Keiretsu Forum, as well as other top tier angel groups.

Keiretsu Capital

Novo Holdings is a holding company specializing in life science investors with a focus on creating long-term value.

Novo Holdings

Put simply, Agilent Ventures invests in private early-stage high-technology companies. The organization focuses on investments in life sciences (instruments, genomics, and proteomics), wireless (WLAN components and test, embedded measurement, and mobile appliance RF components), and wireline/optical communications (high-speed integrated circuits, packaging and manufacturing technology, and optical components). The firm has active investments in Acer Technology Ventures Asia Pacific, AXSUN Technologies, Infinera, OEwaves, SiRiFIC Wireless, TelASIC Communications, and Tropian. Agilent Ventures is a unit of Agilent Technologies.

Agilent Ventures

Seabed VC invests in early stage start-ups looking for seed capital. We believe that magic happens when talented founders and supportive investors work closely to solve difficult problems. We invest with an open mind and take bets in ideas that mainstream VCs won't.

Seabed VC

Soleus Capital

Alumni Ventures Group provides high-quality, diversified venture portfolios to individual investors who previously haven't had access to VC. It helps accredited alums from top entrepreneurial schools invest together in the ventures of fellow alums. The firm backs companies with an alumni connection and an institutional lead investor with expertise in the space. AVG also offers focused funds that allow any accredited investor access to a venture portfolio, diversified by type, sector, stage, and geography. Beth Obermiller, Michael Madden, and Mike Collins co-founded the firm in Manchester, New Hampshire in 2013.

Alumni Ventures

Mission Bio

Mission Bio delivers targeted solutions for high-impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first and only single-cell multi-omics platform, enabling genotype and phenotype from the same cell and precise detection of heterogeneity in disease progression and treatment response. Application areas include oncology blood cancers, solid tumors, and genome editing validation.

Mission Bio is a biotechnology company that specializes in developing and commercializing single-cell multi-omics solutions for precision medicine. The company's flagship product, the Tapestri Platform, is a single-cell genomics and proteogenomic characterization tool that allows researchers and clinicians to have a deeper knowledge of disease profiles by identifying disease subtypes, predicting disease progression, and understanding treatment response, and thereby accelerating discovery, development, and delivery of precision medicine. The platform also facilitates product characterization in cell therapeutics.

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Logo - Mission Bio Appoints Roman Haehn as Chief Commercial Officer to Drive Market Expansion

To expand the reach of Mission Bio's Tapestri Platform, a device that enables precision analysis of DNA and protein at the cellular level.

Software analytics platforms that integrate multiple omics datasets (genomics, transcriptomics, proteomics, and metabolomics) to gain insights and support target discovery, drug development, clinical trials, and diagnostics.

Mission Bio is a biotechnology company that specializes in developing and commercializing single-cell multi-omics solutions for precision medicine. The company's flagship product, the Tapestri Platform, is a single-cell genomics and proteogenomic characterization tool that allows researchers and clinicians to have a deeper knowledge of disease profiles by identifying disease subtypes, predicting disease progression, and understanding treatment response, and thereby accelerating discovery, development, and delivery of precision medicine. The platform also facilitates product characterization in cell therapeutics.Furthermore, the company claims that the platform's latest version launched in May 2023 captures 4x the number of cells compared to the previous chemistry. In addition, Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously from the same sample at single-cell resolution. It is being used by customers at research centers, pharmaceutical, and diagnostics companies to develop treatments, and, eventually, as cures for cancer.Key Customers and PartnershipsThe company has several key partnerships with pharma and biopharma companies including Amgen, Merck, Abbvie, and CRISPR Therapeutics.The company partnered with clinical diagnostic company <a href="https://sp-edge.com/updates/17651">Fulgent Genetics </a>(April 2023) to expand the accessibility of single-cell multiomics for drug development and clinical research, single-cell bioinformatics company Abiosciences (in December 2022) to co-develop bioinformatics packages for translational and clinical research applications in hematological cancers, laboratory automation solution company S2 Genomics (April 2022) to offer a single streamlined workflow for solid tumor applications from sample prep through analysis, and single-cell omics technology company SequMed (December 2021) to expand its product and services offerings into China.

<div>
 
 Praxis Precision Medicines is a clinical-stage biopharmaceutical company that develops precision medicine for central nervous system disorders based on neuronal imbalance caused by genetic mutations.
 
 
 The company has four clinical-stage product candidates in its pipeline for treating disorders such as depression, epilepsy, movement disorders, and pain syndromes. The company&rsquo;s drug candidates include 1) PRAX-944, which is an inhibitor for essential tremor disorder linked to Parkinson&rsquo;s disease and is set to begin Phase 3 in mid-2023, 2) PRAX-222 in Phase 2 of clinical trials targets the SCN2A gene most commonly associated with early-onset epilepsy, 3) PRAX-562 was designed to block persistent sodium for patients suffering from rare diseases such as headache disorders and severe seizures and completed Phase 1 of clinical trials, and 4) PRAX-628 in Phase 2 clinical trials for treating focal epilepsy that originates in one side or area of the brain and affects one side of the body. Additionally, the firm has six pre-clinical drug candidates.
 
 
 Funding and financials
 
 
 The company went public in October 2020, trading on the Nasdaq Global Select Market under the ticker symbol &ldquo;PRAX&rdquo;. 
 <a href="https://sp-edge.com/updates/19453">
 In June 2023 
 </a>
 , the company announced an underwritten public offering of its common shares and pre-funded warrants, to raise approximately USD 59.1 million. The capital raised was used to support the company&rsquo;s ongoing operations and strategic initiatives, furthering the development of its pipeline and potential future endeavors.
 
 
 For the year 
 <a href="https://sp-edge.com/updates/16211">
 2022
 </a>
 , net losses increased by 28% YoY to USD 214 million arising from a significant increase in R&amp;D expense (up by 29% YoY). For the six months ended June 2023, the company is yet to generate revenue from drugs, however received collaboration revenue of USD 1.5 million. Further, it reported a decline in net loss by 43.0% YoY to USD 34.3 million. Its cash and cash equivalent as of June 2023 was at USD 124.3 million, compared to USD 61.6 million in December 2022, which the company believes will be adequate to fund operations till Q1 2025. 
 
</div>

Praxis Precision Medicines

<div>
 
 Mirati Therapeutics is a commercial-stage biotechnology company developing oncology-targeted therapies to address KRAS mutations present in 25% of tumors, including lung, colorectal and pancreatic cancers. Mirati&rsquo;s lead product KRAZATI (adagrasib/ MRTX849) is an oral&nbsp; KRASG12C inhibitor approved in 2022 for certain non-small cell lung cancers.The company also has sitravatinib, a multi-kinase inhibitor, in Phase 3 trials for non-small cell lung cancer in combination with a Bristol-Myers Squibb checkpoint inhibitor.
 
 
 
 
 Additionally, Mirati is advancing multiple early-stage programs including KRAS G12D inhibitor MRTX1133 for pancreatic and colorectal cancers, which entered Phase 1 in 2023, as well as a synthetic lethal inhibitor MRTX1719. In December 2022, the company submitted an IND application for MRTX1133, a potent and selective KRAS G12D inhibitor, which was cleared by the FDA in January 2023. 
 
 
 Key partnerships and customers
 
 
 
 
 Mirati has multiple partnerships with leading biopharma companies to advance its pipeline, including discovery collaborations with Pfizer and clinical collaborations with Novartis, Boehringer Ingelheim, and 
 <a href="https://sp-edge.com/updates/14345">
 Incyte
 </a>
 . The company also has licensing agreements with BeiGene for sitravatinib and Zai Lab for MRTX849 in certain Asian markets.
 
 
 
 
 
 Funding and Financials
 
 
 
 
 The company went public in June 2013 to trade on Nasdaq under the ticker symbol &ldquo;MRTX&rdquo;. In August 2023, the company closed an 
 <a href="https://sp-edge.com/updates/20988">
 underwritten public offering
 </a>
 at USD 345 million. The new funds were used towards drug development and leadership expansion.&nbsp;
 
 
 
 
 <a href="https://sp-edge.com/updates/16725">
 For the year 2022 
 </a>
 , the firm's net losses increased to USD 740.9 million from USD 581.8 million. Net product revenue for the full year amounted to USD 0.7 million arising from the sale of KRAZATI, which received FDA approval for its commercial launch in December 2022. 
 
</div>

Mirati Therapeutics

<div>
 
 Tvardi Therapeutics is a clinical-stage biotechnology company developing precision medicine for different cancers, chronic inflammatory diseases, and fibrotic diseases. The company&rsquo;s pipeline focuses on the development of small-molecule inhibitors of STAT3, a regulatory protein that allows cancer cells to evade the immune system and survive.
 
 
 The company&rsquo;s orally administered monotherapy and lead product, TTI-101, is in Phase 1 clinical trials for patients with advanced solid tumors who have failed all other lines of therapy. Additionally, the drug is in preclinical trials for treating fibrosis and inflammation. The company is also developing TTI-102, a next-generation STAT3 inhibitor that is structurally similar but chemically different from TTI-101.&nbsp;
 
 
 Founded in 2017, the Texas-based company closed a Series B funding round in June 2021, which brought total funding to USD 81 million and the proceeds will be used to advance Tvardi&rsquo;s drug candidates through its clinical data readouts in mid-stage trials for cancer and fibrosis.
 
</div>

Tvardi Therapeutics

<div>
 
 Tango Therapeutics is a clinical-stage biotech company developing precision oncology therapies targeting synthetic lethality in cancer which leads to cell death. Its discovery platform identifies novel targets to develop drugs focused on: 1) countering tumor suppressor gene loss to help the immune system recognize and kill cancer cells, and 2) reversing cancer cell evasion of the immune system.
 
 
 
 
 Tango has five pipeline programs, including lead candidate TNG908, an inhibitor for multiple cancer indicators. The FDA approved TNG908's IND in January 2022 and granted it Orphan Drug Designation. TNG908 is in Phase I/II trials, with preliminary efficacy data expected in H1 2023. Tango also plans to file INDs for TNG260 (STK11 mutant cancers) and TNG348 (BRCA1/2-mutant cancers). In 
 <a href="https://www.globenewswire.com/news-release/2023/01/25/2595034/0/en/Tango-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-TNG462-Provides-Additional-Business-Updates.html">
 January 2023
 </a>
 , the FDA cleared the IND for TNG462, a next-gen PRMT5 inhibitor for cancers with MTAP deletion.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 
 Outside its pipeline, the company also entered into a collaborative partnership with big pharma Gilead Sciences Inc., in October 2018 which was later expanded for two years in August 2020 to identify new immune evasion targets.
 
 
 
 
 Funding and financials&nbsp;
 
 
 
 
 
 Tango went public in August 2021 via a SPAC deal, trading on Nasdaq under the ticker symbol &ldquo;TNGX&rdquo;, and the company received gross proceeds of USD 353 million. In August 2023, the company raised USD 80 million via a 
 <a href="https://sp-edge.com/updates/20955">
 private placement
 </a>
 , which was led by Nextech. The new funds were used toward expanding its TNG908 and TNG462 PRMT5 programs to various other indications.
 
 
 
 
 Tango has not yet generated any drug sales and does not expect to do so for several years. However, for the full-year the company reported collaboration revenue of USD 24.9 million (down 4.42% YoY) and a net loss of USD 108.2 million (up 85.9% YoY).
 
 
 
</div>

Tango Therapeutics

<div>
 
 IDEAYA Biosciences is a clinical-stage biotech developing precision cancer therapies based on synthetic lethality - when specific gene mutations pair to cause cell death. The company also studies combining synthetic lethality with immunotherapies and DNA damage to enhance treatment efficacy. While current drugs target limited mutations like BRCA1/2, IDEAYA aims to treat broader genetic subpopulations.&nbsp;
 
 
 
 
 Its pipeline includes synthetic lethality-driven precision medicines across four potential first-in-class clinical-stage product candidates. Of these, the company owns/controls commercial rights of the three most-advanced of these product candidates: darovasertib, IDE397, and IDE161. As of May 2024, the company was also advancing Werner Helicase program for which a development candidate has been selected in collaboration with GlaxoSmithKline, and, subject to investigational new drug-, or IND-, enabling studies, are targeting an IND in 2024. In addition. the company also works on multiple earlier-stage preclinical programs. 
 
 
 By targeting specific genetic drivers, IDEAYA advances precision oncology using synthetic lethality approaches. The company is focused on developing novel targeted therapies for patient populations with high unmet need and limited treatment options.&nbsp;&nbsp;
 
 
 In December 2023, IDEAYA Biosciences teamed up with Gilead Sciences to test the combination of IDE397 and Trodelvy in a Phase I clinical trial for MTAP-deletion bladder cancer.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 The company collaborates with pharmaceutical partners to advance its pipeline, including a strategic partnership with GSK in June 2020. The collaboration with GSK covers co-development and commercialization of two synthetic lethality programs. IDEAYA received USD 100 million upfront and USD 20 million in a direct private placement through the GSK deal. In June 2022, IDEAYA announced it would co-develop its Pol Theta candidate with GSK, with a Phase 1 trial starting in the first half of 2023.&nbsp;
 
 
 
 
 IDEAYA also holds an exclusive license from Novartis for LXS196 (IDE196), a PKC inhibitor for metastatic uveal melanoma. Additionally, the company is exploring IDE196 combinations with Pfizer and its potential in other rare skin diseases. In July 2022, IDEAYA signed an agreement with Amgen to evaluate IDE397 with Amgen's AMG 193 in solid tumors. Strategic pharma partnerships help advance and expand IDEAYA's pipeline of synthetic lethality precision oncology programs.
 
 
 
 
 Funding and financials
 
 
 
 
 
 The company was listed on the Nasdaq Global Select Market under the ticker symbol &ldquo;IDYA&rdquo; in May 2019, raising USD 50 million via an initial public offering. In September 2022, the company raised USD 92 million.&nbsp;
 
 
 
 
 For 2022, the company reported a net loss of USD 58.7 million (up 17.9% YoY) while collaboration revenue was USD 50.9 million (up 82.3% YoY). 
 
 
 On October 24, 2023, IDEAYA Biosciences priced an underwritten public offering of 5 million shares of common stock and pre-funded warrants to purchase 319,150 shares of common stock. The common stock offered was priced at USD 23.50 per share, while the exercise price of a pre-funded warrant was USD 0.0001. The offering was expected to bring in approximately USD 125 million in gross proceeds.
 
 
 
</div>

IDEAYA Biosciences

Companies providing genetic tests to identify individuals with high risk or at-risk of having hereditary disease, aid physicians with a diagnosis, and support clinical decision making.

Secure cloud-based platforms and data sharing networks that collect, index, store, and analyze large amounts of health data and patient population data sets from sources including genomic, clinical, wearables, imaging, and population data.

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

Companies that study intergenomic variations in genes associated with drug response and metabolism to match patients with the appropriate drug and dosage.

Companies that develop an in-vitro medical device or imaging tools and tests that identify genetic mutations for both diagnostic (nature of the disease) and prognostic (likely course of the disease) purposes, allowing providers to match a patient to a specific drug or therapy.

Some companies leverage AI/ML to develop tailored medication

Considers individual variability in genes, environment, and lifestyle for each person

Genomics is used across all the segments of precision medicine from diagnostic solutions to treatments

AI/ML analyzes genomic data to find drug targets, predict disease progression, and treatment response

PROMINENT_CATEGORY

<div>
 Mission Bio has introduced a new product, the Tapestri Single-cell Multiple Myeloma Multiomics Solution. It is designed to enhance research and therapy development for multiple myeloma by providing in-depth information about the disease on a single-cell level.
 The solution features a variety of flexible assays that offer meticulous insights into the cellular and genetic structure of myeloid progression, resistant therapy, and disease recurrence. Included in the solution, there is a Multiple Myeloma DNA Panel for gene focus, a Genome-wide CNV Panel for evaluating clonal diversity, a Multiple Myeloma Antibody Cocktail for classifying cell types and identifying targets, as well as an automated data analysis and reporting system.&nbsp;
 According to the company, the solution has the potential to enhance immunotherapy applications and uncover the molecular origins of multiple myeloma by supplying early signs of therapeutic efficiency.
</div>

Mission Bio

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless